Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100-mg in treatment-naïve HIV-infected patients

HIV Medicine

Volumn 11, Issue 10, 2010, Pages 666-669

  Lambert Niclot, S ^a   Machouf, N ^b   Peytavin, G ^c   Soulie, C ^a   Wirden, M ^a   Simon, A ^a   Murphy, R L ^a,d   Katlama, C ^a   Thomas, R ^b   Calvez, V ^a   Marcelin, A G ^a  

^a INSERM   (France)

^b Clinique Medicale l'Actuel   (Canada)

^c BICHAT HOSPITAL   (France)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Atazanavir; Inhibitory quotient; Protein binding; Resistance

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; DIDANOSINE PLUS LAMIVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CALCULATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITORY QUOTIENT; MAJOR CLINICAL STUDY; MALE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN BINDING; VIROLOGY; VIRUS MUTATION;

ADULT; AGED; BLOOD PROTEINS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OLIGOPEPTIDES; PROTEIN BINDING; PYRIDINES; RITONAVIR; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77958559504     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00839.x     Document Type: Article

References (23)

1. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 2003; 63: 741-753.
2. Burger DM, Aarnoutse RE, Hugen PW. Pros and cons of therapeutic drug monitoring of antiretroviral agents. Curr Opin Infect Dis 2002; 15: 17-22.
3. Morse GD, Catanzaro LM, Acosta EP. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect Dis 2006; 6: 215-225.
4. Shulman N, Zolopa A, Havlir D et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 2002; 46: 3907-3916.
5. Casado JL, Moreno A, Sabido R et al. Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response. AIDS 2003; 17: 262-264.
6. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005; 44: 1035-1050.
7. Lazdins JK, Mestan J, Goutte G et al. In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis 1997; 175: 1063-1070.
8. Boffito M, Hoggard PG, Lindup WE et al. Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit 2004; 26: 35-39.
9. Anderson PL, Brundage RC, Bushman L, Kakuda TN, Remmel RP, Fletcher CV. Indinavir plasma protein binding in HIV-1-infected adults. AIDS 2000; 14: 2293-2297.
10. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Available at (accessed 24 April 2008).
11. EACS. The European AIDS Clinical Society EACS guidelines. Available at (accessed 23 April 2008).
12. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827-843.
13. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-655.
14. Zhu L, Liao S, Child M et al. CASTLE Study: Pharmacokinetics and Inhibitory Quotient of Boosted Once Daily Atazanavir Compared to Twice Daily Lopinavir in HIV-1 Infected, Treatment Naive Subjects. 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, LA, 2008 [Abstract O23].
15. Marsh KC, Eiden E, McDonald E. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 704: 307-313.
16. Bristol-Myers Squibb. REYATAZ (atazanavir sulfate) Capsules Package Insert. Available at (accessed February 2010).
17. Eron JJ, Feinberg J, Kessler HA et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis 2004; 189: 265-272.
18. Sekar V, Vanden Abeele C, Van Baelen B et al. Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study. 9th International Workshop on Pharmacology of HIV Therapy. New Orleans, 2008 [Abstract P42].
19. Tibotec. PREZISTA: Summary of Product Characteristics. EMEA/H/C/707 European Public Assessment. Available at (accessed February 2010).
20. Lamotte C, Landman R, Peytavin G et al. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Antivir Ther 2004; 9: 247-256.
21. U.S Food and Drug Administration. Invirase softgel capsules NDA no. 021785 Label information approved on 07/11/2007. Available at (accessed February 2010).
22. U.S Food and Drug Administration. Lexiva NDA no. 021548 Label information approved on 09/11/2009. Available at (accessed February 2010).
23. Sadler BM, Gillotin C, Lou Y, Stein DS. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001; 45: 30-37.